JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Strona główna・Stock List・Gossamer Bio Inc

Gossamer Bio Inc

Closed

SectorHealthcare

1.84 2.79

Buy Sell

Overview

Share price change

24h

Current

Min

1.84

Max

1.91

Key metrics
By Trading Economics
Income	-3.6M -37M
Sales	510K 9.9M
Profit margin	-370.492
Employees	144
EBITDA	-1.9M -34M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+400% upside

Dividends
By Dow Jones
Next Earnings	8 sie 2025

Market Stats
By TradingEconomics
Market Cap	148M 398M
Previous open	-0.95
Previous close	1.84

News Sentiment

By Acuity

100%

361 / 375 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

1.06 / 1.23 Support & Resistance

Gossamer Bio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 lip 2025, 17:53 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 lip 2025, 15:58 UTC

Earnings

Major Market Movers

Aon Shares Rise After 2Q Earnings Beat

25 lip 2025, 15:08 UTC

Major Market Movers

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 lip 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 lip 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 lip 2025, 20:40 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 lip 2025, 20:10 UTC

Earnings

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 lip 2025, 19:56 UTC

Earnings

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 lip 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 lip 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 lip 2025, 19:01 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 lip 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 lip 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 lip 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 lip 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 lip 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 lip 2025, 17:38 UTC

Major Market Movers

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 lip 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 lip 2025, 17:13 UTC

Earnings

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 lip 2025, 16:46 UTC

Earnings

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 lip 2025, 16:45 UTC

Earnings

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 lip 2025, 16:27 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 lip 2025, 16:02 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 lip 2025, 15:34 UTC

Earnings

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 lip 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 lip 2025, 15:05 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 lip 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 lip 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 lip 2025, 14:36 UTC

Market Talk

Earnings

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer Comparison

Price change

Gossamer Bio Inc Forecast

Price Target

By TipRanks

400% upside

12 Months Forecast

Average 9.2 USD 400%

High 15 USD

Low 4 USD

Based on 7 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Gossamer Bio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.06 / 1.23Support & Resistance

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

361 / 375 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.